I see there are sweet FA comments on the S66 thread.
Keen to get people's views on what they are paying for Bio-E - i.e. is the multiple reasonable against forecasted EBITDA? Are they overpaying or is this appropriate?
No one concerned with the amount of dilution we're going to see on the back of this?
Ann: Star Combo Investor Presentation, page-11
Add S66 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.85M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6360 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 18242 | 2 |
View Market Depth
| Last trade - 16.12pm 28/06/2024 (20 minute delay) ? |
| S66 (ASX) Chart |
Day chart unavailable